** Shares of drug developer Keros Therapeutics KROS.O fall ~71% to $20 premarket
** KROS says it has halted dosing of 3.0 mg and 4.5 mg doses of its high blood pressure treatment in a mid-stage study due to fluid buildup around the heart
** Dosing in the 1.5 mg/kg arm will continue after a risk-benefit review by an independent monitoring committee - KROS
** Co has notified the U.S. FDA about it and expects to present data from all treatment arms in Q2 2025 - KROS
** As of last close, stock has fallen 25.7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。